Moderate to Severe Plaque Psoriasis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine

Moderate to Severe Plaque Psoriasis companies are Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite Biopharma, Bio-thera solutions, AbbVie, Sinocelltech, Jansen research and development, Innovent Biologics, Aurigene discovery, Affibody, GlaxoSmithKline, Abcentra

Moderate to Severe Plaque Psoriasis Pipeline constitutes 30+ key companies continuously working towards developing 30+ Moderate to Severe Plaque Psoriasis treatment therapies, analyzes DelveInsight.

Moderate to Severe Plaque Psoriasis Overview:

Moderate to severe plaque psoriasis is the most prevalent form of psoriasis, affecting 80% to 90% of individuals with the condition. It is an autoimmune disease that accelerates skin cell production, leading to the formation of thick, scaly patches known as plaques. These plaques typically appear on the elbows, knees, scalp, and back, and may also affect the nails, causing discoloration, pitting, or detachment. The condition can be triggered or worsened by infections, stress, or skin injuries, and symptoms tend to fluctuate, with periods of remission followed by flare-ups.

While the exact cause of plaque psoriasis remains unclear, genetics play a significant role, with around one-third of cases having a family history. Researchers have identified specific gene mutations (PSORS1-PSORS9) linked to the condition, though environmental factors such as infections or toxic exposure may also contribute. Diagnosis is usually based on the appearance of the skin, but in some cases, a biopsy may be required to differentiate it from other skin conditions.

Plaque psoriasis can significantly impact a person's confidence and well-being. Although there is no cure, treatments aim to reduce flare-ups and manage symptoms. Common therapies include topical corticosteroids, phototherapy (UV light exposure), vitamin D3 analogs, and retinoids. While the condition persists throughout life, advancements in immunology and autoimmune research have led to more effective treatment strategies, improving patients' quality of life.

Request for a detailed insights report on Moderate to Severe Plaque Psoriasis pipeline insights @ https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Moderate to Severe Plaque Psoriasis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Moderate to Severe Plaque Psoriasis Therapeutics Market.

Key Takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report

DelveInsight's Moderate to Severe Plaque Psoriasis pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Moderate to Severe Plaque Psoriasis treatment.
Key Moderate to Severe Plaque Psoriasis companies such as Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite Biopharma, Bio-thera solutions, AbbVie, Sinocelltech, Jansen research and development, Innovent Biologics, Aurigene discovery, Affibody, GlaxoSmithKline, Abcentra, and others are evaluating new drugs for Moderate to Severe Plaque Psoriasis to improve the treatment landscape.
Promising Moderate to Severe Plaque Psoriasis pipeline therapies in various stages of development include BMS-986165, AK111, and others.

Recent breakthroughs in the Moderate to Severe Plaque Psoriasis Pipeline Segment:

In November 2025, Johnson & Johnson announced that its oral medication, icotrokinra, met the main goals in a late-stage trial for treating moderate-to-severe plaque psoriasis. The once-daily pill was effective in achieving clear or almost clear skin and reducing the severity of patches. At week 16, 64.7% of patients showed significant skin clearance, and 49.6% exhibited a reduction in plaque severity, compared to 8.3% and 4.4% in the placebo group, respectively.
In 2025, Arcutis Biotherapeutics experienced a notable stock rally, driven by its focus on dermatology treatments. The company introduced three FDA-approved drugs within two years and aims for two more approvals in 2025. Their flagship product, Zoryve, addresses plaque psoriasis and seborrheic dermatitis and boasts a foam version for eczema.

Moderate to Severe Plaque Psoriasis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Moderate to Severe Plaque Psoriasis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Moderate to Severe Plaque Psoriasis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Moderate to Severe Plaque Psoriasis market.

Download our free sample page report on Moderate to Severe Plaque Psoriasis pipeline insights @ https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Moderate to Severe Plaque Psoriasis Emerging Drugs

BMS-986165 : Bristol-Myers Squibb
AK111: Akeso Biopharma

Moderate to Severe Plaque Psoriasis Companies

Around 30 or more key companies are actively developing therapies for moderate to severe plaque psoriasis. Among them, Bristol-Myers Squibb has the most advanced drug candidates, currently in the pre-registration stage.

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Moderate to Severe Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Moderate to Severe Plaque Psoriasis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Moderate to Severe Plaque Psoriasis Therapies and Key Companies: Moderate to Severe Plaque Psoriasis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Moderate to Severe Plaque Psoriasis Pipeline Therapeutic Assessment
• Moderate to Severe Plaque Psoriasis Assessment by Product Type
• Moderate to Severe Plaque Psoriasis By Stage
• Moderate to Severe Plaque Psoriasis Assessment by Route of Administration
• Moderate to Severe Plaque Psoriasis Assessment by Molecule Type

Download Moderate to Severe Plaque Psoriasis Sample report to know in detail about the Moderate to Severe Plaque Psoriasis treatment market @ Moderate to Severe Plaque Psoriasis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Moderate to Severe Plaque Psoriasis Current Treatment Patterns
4. Moderate to Severe Plaque Psoriasis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Moderate to Severe Plaque Psoriasis Late-Stage Products (Phase-III)
7. Moderate to Severe Plaque Psoriasis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Moderate to Severe Plaque Psoriasis Discontinued Products
13. Moderate to Severe Plaque Psoriasis Product Profiles
14. Moderate to Severe Plaque Psoriasis Key Companies
15. Moderate to Severe Plaque Psoriasis Key Products
16. Dormant and Discontinued Products
17. Moderate to Severe Plaque Psoriasis Unmet Needs
18. Moderate to Severe Plaque Psoriasis Future Perspectives
19. Moderate to Severe Plaque Psoriasis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Moderate to Severe Plaque Psoriasis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.